We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 511

Personalized medicine: patent issues in Canada and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • October 16 2014

Canada Introduction 'Personalized medicine', in its broadest aspects, is essentially the tailoring of treatments to individual characteristics, needs

Canadian Competition Bureau provides preliminary guidance on pharma patent settlements

  • McCarthy Tétrault LLP
  • -
  • Canada
  • -
  • October 14 2014

Settlements of patent litigation between brand name and generic pharmaceutical companies have been the subject of significant antitrustcompetition

Patent not eligible for listing: patent claiming one medicinal ingredient,but directed to a fixed-dose combination of medicines

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • October 15 2014

This was an appeal from two decisions for three proceedings before Prothonotary Milczynski, in which she determined that a patent could not be listed

Canada-EU Comprehensive Economic and Trade Agreement negotiation completed: additional protection for innovative pharmaceutical products

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada, European Union
  • -
  • October 1 2014

On September 26, 2014, Canada and the EU announced completion of negotiations on the Canada-EU Comprehensive Economic and Trade Agreement (CETA

Canada and the EU successfully conclude CETA: what it means to the pharmaceutical industry

  • McCarthy Tétrault LLP
  • -
  • Canada, European Union
  • -
  • September 30 2014

On September 26, 2014, Prime Minister Harper announced that Canada and the European Union have successfully concluded negotiations on a new trade

Dow prevails over Nova in polymer patent suit

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • October 8 2014

The Dow Chemical Company (“Dow”) has prevailed in a Canadian patent infringement suit against Nova Chemicals Corporation (“Nova”) relating to Nova’s

Methods of medical treatment and dosage claims

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • June 28 2011

In Canada, claims to methods of medical treatment are considered to fall outside the definition of invention according to section 2 of the Patent Act and a decision of the Supreme Court of Canada

CETA text released: Patent term restoration for pharmaceuticalbiologic patents coming to Canada

  • Smart & Biggar/Fetherstonhaugh
  • -
  • Canada
  • -
  • September 29 2014

As reported in the IP Update, Text of CETA released the text of CETA was released on September 26, 2014. As reported in that article, CETA, Chapter

Teva v Pfizer, or the “Viagra saga”: if there is no quid proper disclosure there can be no quo exclusive monopoly rights

  • Fasken Martineau DuMoulin LLP
  • -
  • Canada
  • -
  • November 19 2012

Sildenafil is the active ingredient in Viagra, the blockbuster potency-enhancing drug marketed by Pfizer

Purdue Pharma denied patent listing

  • Heenan Blaikie LLP
  • -
  • Canada
  • -
  • October 5 2010

Purdue Pharma v. Attorney General of Canada and Minister of Health, 2010 FC 738, an application for a judicial review of a decision made by the Office of Patented Medicines and Liaison (“OPML”), the Federal Court found that Purdue Pharma (“Purdue”) was not entitled to list a patent for oxycodone on Health Canada’s Patent Register in respect of its TARGIN oxycodonenaloxone combination product